4.4 Article

Human iPSC-derived hepatocytes in 2D and 3D suspension culture for cryopreservation and in vitro toxicity studies

Journal

REPRODUCTIVE TOXICOLOGY
Volume 111, Issue -, Pages 68-80

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.reprotox.2022.05.005

Keywords

Human induced pluripotent stem cells; Hepatocytes; In vitro toxicology; Nanoluciferase reporter; Miniaturization; Hepatic organoids; Cryopreservation; Upscaling

Funding

  1. Innovative Medicines Initiative 2 Joint Undertaking (JU) under the 'EBiSC2'grant [821362]
  2. European Unions Horizon 2020 research and innovation programme
  3. EFPIA
  4. Danish Ministry of Higher Education and Science [DK-1034-00006B]

Ask authors/readers for more resources

In this study, an optimized protocol for generating hepatocyte-like cells (HLCs) and hepatic organoids from hiPSCs was presented. The protocol was further translated to scalable suspension-based bioreactors to meet the increasing demand of hepatic cells. Cryopreservation approaches were also analyzed to ensure the maintenance of organoid phenotype.
Hepatocytes are of special interest in biomedical research for disease modelling, drug screening and in vitro toxicology. Human induced pluripotent stem cell (hiPSC)-derived hepatocytes could complement primary human hepatocytes due to their capability for large-scale expansion. In this study, we present an optimized protocol for the generation of hepatocyte-like cells (HLCs) from hiPSC in monolayer (2D) and suspension culture (3D) for production of organoids. A protocol was initially optimized in 2D using a gene edited CYP3A4 Nanoluciferase reporter hiPSC line for monitoring the maturity of HLCs and cryopreservation of definitive endoderm (DE) cells. The protocol was optimized for microwell cultures for high-throughput screening to allow for a sensitive and fast readout of drug toxicity. To meet the increasing demand of hepatic cells in biomedical research, the differentiation process was furthermore translated to scalable suspension-based bioreactors for establishment of hepatic organoids. In pilot studies, the technical settings have been optimized by adjusting the initial seeding density, rotation speed, inoculation time, and medium viscosity to produce homogeneous hepatic organoids and to maximize the biomass yield (230 organoids/ml). To speed up the production process, cryopreservation approaches for the controlled freezing of organoids were analysed with respect to cell recovery and marker expression. The results showed that cryopreserved organoids maintained their phenotype only when derived from hepatocyte progenitors (HPs) at day 8 but not from more mature stages. The establishment of robust protocols for the production of large batches of hepatocytes and hepatic organoids could substantially boost their use in biomedical and toxicology studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available